Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 7/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412345 | 0.91 | P2RY12 (0.49) | USP2P2RY12KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4418832 | 0.87 | P2RY12 (0.54) | USP2P2RY12KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4415214 | 0.86 | P2RY12 (0.49) | USP2P2RY12KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4426718 | 0.85 | P2RY12 (0.49) | P2RY12KMT2AMEN1SMN1; SMN2TP53 | |
| SCHEMBL13635098 | 0.84 | MEN1 (0.53) | P2RY12KMT2AMEN1SMN1; SMN2TP53 | |
| SCHEMBL4422992 | 0.84 | CACNA1G (0.46) | USP2P2RY12TP53MAPTRXFP1 | |
| SCHEMBL4425407 | 0.83 | P2RY12 (0.51) | USP2P2RY12KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL13634873 | 0.82 | P2RY12 (0.52) | P2RY12KMT2AMEN1SMN1; SMN2TP53 | |
| SCHEMBL4413815 | 0.81 | P2RY12 (0.51) | P2RY12KMT2AMEN1SMN1; SMN2TP53 | |
| SCHEMBL4415290 | 0.81 | P2RY12 (0.52) | P2RY12KMT2AMEN1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1668002-B1 | 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS | PORTOLA PHARM INC (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-1668002-B1 | 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS | PORTOLA PHARM INC (US) | 2009-11-11 | — | — | EP | disclosed |
| US-7109332-B2 | 2,4-dioxo-3-quinazolinylaryl sulfonylureas | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050107357-A1 | 2,4-dioxo-3-quinazolinylaryl sulfonylureas | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107357-A1 | 2,4-dioxo-3-quinazolinylaryl sulfonylureas | PFKP, DPP3, P2RY13 | USP2 1446/4885P2RY12 21/4885KMT2A 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.